{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:14:18Z","timestamp":1792808058650,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.annonc.2025.10.006","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T17:57:36Z","timestamp":1760983056000},"page":"180-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4\/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5430-8957","authenticated-orcid":false,"given":"E.L.","family":"Mayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5932-8949","authenticated-orcid":false,"given":"F.-C.","family":"Bidard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4156-9212","authenticated-orcid":false,"given":"Y.H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5911-2400","authenticated-orcid":false,"given":"W.","family":"Janni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cristofanilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6790-6267","authenticated-orcid":false,"given":"G.","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kalinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8080-7960","authenticated-orcid":false,"given":"A.","family":"Brufsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Nowecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0177-0045","authenticated-orcid":false,"given":"S.-C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3874-2782","authenticated-orcid":false,"given":"J.","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1181-5622","authenticated-orcid":false,"given":"M.","family":"Ruiz-Borrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9502-8441","authenticated-orcid":false,"given":"A.","family":"Shai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Karadurmus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Leddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2454-8519","authenticated-orcid":false,"given":"M.S.","family":"Miralles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.H.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2025.10.006_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"issue":"35","key":"10.1016\/j.annonc.2025.10.006_bib2","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1200\/JCO.21.01392","article-title":"Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update","volume":"39","author":"Burstein","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2025.10.006_bib3","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.006_bib4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast Cancer Res"},{"issue":"28","key":"10.1016\/j.annonc.2025.10.006_bib5","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.10.006_bib6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10549-024-07376-w","article-title":"Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(\u2212) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice","volume":"207","author":"Bhave","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.006_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41523-024-00617-7","article-title":"CDK4\/6i-treated HR+\/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape","volume":"10","author":"Chaudhary","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"11","key":"10.1016\/j.annonc.2025.10.006_bib8","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.006_bib9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/annonc\/mdx483","article-title":"Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer","volume":"29","author":"Fribbens","year":"2018","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.006_bib10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1-mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.annonc.2025.10.006_bib12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.annonc.2025.10.006_bib13","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1200\/JCO.1996.14.10.2756","article-title":"The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study","volume":"14","author":"Sprangers","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.10.006_bib14","series-title":"The ECDEU Assessment Manual for Psychopharmacology. Revised edition. Rockville, MD: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration","author":"Guy","year":"1976"},{"issue":"5","key":"10.1016\/j.annonc.2025.10.006_bib15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"issue":"8","key":"10.1016\/j.annonc.2025.10.006_bib16","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and reliability of the US National Cancer Institute\u2019s patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"1","author":"Dueck","year":"2015","journal-title":"JAMA Oncol"},{"issue":"10 Suppl.","key":"10.1016\/j.annonc.2025.10.006_bib17","first-page":"409","volume":"21","author":"Arizmendi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.006_bib18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2025.10.006_bib19","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.annonc.2025.10.006_bib20","doi-asserted-by":"crossref","first-page":"758","DOI":"10.6061\/clinics\/2017(12)07","article-title":"Pain and quality of life in breast cancer patients","volume":"72","author":"Costa","year":"2017","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.annonc.2025.10.006_bib21","article-title":"Pain associated with breast cancer: etiologies and therapies","volume":"4","author":"Doan","year":"2023","journal-title":"Front Pain Res (Lausanne)"},{"key":"10.1016\/j.annonc.2025.10.006_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104556","article-title":"Abstract 1O: Kinetics and determinants of blood ESR1 mutation under AI and palbociclib in HR+\/HER2- metastatic breast cancer patients in the PADA-1 trial","volume":"10","author":"Cabel","year":"2025","journal-title":"ESMO Open"},{"issue":"313","key":"10.1016\/j.annonc.2025.10.006_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac7551","article-title":"Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer","volume":"7","author":"Schiavon","year":"2015","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.006_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm3010001","article-title":"Treatment and prevention of bone metastases from breast cancer: a comprehensive review of evidence for clinical practice","volume":"3","author":"Li","year":"2014","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.annonc.2025.10.006_bib25","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S0885-3924(02)00497-9","article-title":"Cancer pain and psychosocial factors: a critical review of the literature","volume":"24","author":"Zaza","year":"2002","journal-title":"J Pain Symptom Manage"},{"issue":"10","key":"10.1016\/j.annonc.2025.10.006_bib26","first-page":"8367","article-title":"Association of change in health-related quality of life and treatment discontinuation in metastatic breast cancer: a post hoc, exploratory analysis of two randomized clinical trials","volume":"30","author":"Kawahara","year":"2022","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2025.10.006_bib27","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0643","article-title":"Association of disease progression with health-related quality of life among adults with breast, lung, pancreatic, and colorectal cancer","volume":"3","author":"Marschner","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.annonc.2025.10.006_bib28","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.breast.2017.08.008","article-title":"Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry","volume":"37","author":"Muller","year":"2018","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.annonc.2025.10.006_bib29","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10549-018-4769-z","article-title":"Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2","volume":"170","author":"Verma","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.annonc.2025.10.006_bib30","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920943065","article-title":"Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)","volume":"12","author":"Harbeck","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2025.10.006_bib31","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/annonc\/mdy012","article-title":"Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial","volume":"29","author":"Rugo","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.006_bib32","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12955-018-1055-z","article-title":"Distribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review","volume":"16","author":"Ousmen","year":"2018","journal-title":"Health Qual Life Outcomes"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2025.10.006_bib33","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2025.43.16_suppl.1001","article-title":"Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator\u2019s choice standard endocrine therapy, or imlunestrant + abemaciclib: results from the phase III EMBER-3 trial","volume":"43","author":"Curigliano","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.10.006_bib34","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1634\/theoncologist.2019-0551","article-title":"Health-related quality of life in MONARCH 2: abemaciclib plus fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy","volume":"25","author":"Kaufman","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2025.10.006_bib35","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.breast.2020.09.008","article-title":"Ribociclib plus fulvestrant for advanced breast cancer: health-related quality-of-life analyses from the MONALEESA-3 study","volume":"54","author":"Fasching","year":"2020","journal-title":"Breast"},{"issue":"10","key":"10.1016\/j.annonc.2025.10.006_bib36","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1002\/cncr.28010","article-title":"Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial","volume":"119","author":"Burris","year":"2013","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.annonc.2025.10.006_bib37","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1200\/JCO.20.01139","article-title":"Patient-reported outcomes in patients with PIK3CA-mutated hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer from SOLAR-1","volume":"39","author":"Ciruelos","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.006_bib38","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/annonc\/mdw139","article-title":"Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial","volume":"27","author":"Harbeck","year":"2016","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2025.10.006_bib39","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S1470-2045(24)00373-5","article-title":"Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"25","author":"Oliveira","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2025.10.006_bib40","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2023.04.027","article-title":"Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: a synthesis across 21 clinical trials involving nine different cancer types","volume":"188","author":"Musoro","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2025.10.006_bib41","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejca.2019.10.031","article-title":"Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer","volume":"125","author":"Mierzynska","year":"2020","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.annonc.2025.10.006_bib42","doi-asserted-by":"crossref","first-page":"e1346","DOI":"10.1634\/theoncologist.2020-0084","article-title":"Health-related quality of life in MONARCH 3: abemaciclib plus an aromatase inhibitor as initial therapy in HR+, HER2- advanced breast cancer","volume":"25","author":"Goetz","year":"2020","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.annonc.2025.10.006_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105082","article-title":"Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial","volume":"10","author":"Hu","year":"2025","journal-title":"ESMO Open"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342504949X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342504949X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T05:44:38Z","timestamp":1773899078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375342504949X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S092375342504949X"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.10.006","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4\/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}